FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104660811> ?p ?o ?g. }

• W2104660811 endingPage "102" @default.
• W2104660811 startingPage "98" @default.
• W2104660811 abstract "No AccessJournal of UrologyClinical Urology: Original Articles1 Jul 1999PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER SUSAN K. QUELLA, CHARLES L. LOPRINZI, JEFF SLOAN, PAUL NOVOTNY, EDITH A. PEREZ, PATRICK A. BURCH, STANLEY J. ANTOLAK, and THOMAS M. PISANSKY SUSAN K. QUELLASUSAN K. QUELLA More articles by this author , CHARLES L. LOPRINZICHARLES L. LOPRINZI More articles by this author , JEFF SLOANJEFF SLOAN More articles by this author , PAUL NOVOTNYPAUL NOVOTNY More articles by this author , EDITH A. PEREZEDITH A. PEREZ More articles by this author , PATRICK A. BURCHPATRICK A. BURCH More articles by this author , STANLEY J. ANTOLAKSTANLEY J. ANTOLAK More articles by this author , and THOMAS M. PISANSKYTHOMAS M. PISANSKY More articles by this author View All Author Informationhttps://doi.org/10.1097/00005392-199907000-00024AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Hot flashes may be a significant clinical problem in men undergoing androgen deprivation therapy with gonadotropin releasing hormone analogues, oral antiandrogens and/or surgical bilateral orchiectomy. Anecdotal information suggests that a low dose of the relatively new antidepressant venlafaxine may abrogate this clinical problem. We developed the current pilot trial to investigate further whether venlafaxine alleviates hot flashes in such men. Materials and Methods: The study included men in whom substantial hot flashes were associated with androgen deprivation therapy. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period when no therapy was given for hot flashes, as well as for the next 4 weeks when study participants received 12.5 mg. venlafaxine orally twice daily. Questionnaires completed during the 4 weeks of venlafaxine therapy also documented data on potential drug toxicity. Results: Of the 16 evaluable patients who completed the study 10 (63%) had a greater than 50% decrease in hot flash score, as determined using the formula, frequency x severity, by week 4 of treatment versus the baseline week. Median weekly hot flash scores decreased 54% from baseline during week 4 of venlafaxine therapy. Average incidence of severe and very severe hot flashes was reduced from 2.3 daily at baseline to 0.6 daily at study end (p = 0.003). Therapy was generally well tolerated. Conclusions: Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy. Further evaluation of this compound for alleviating hot flashes is indicated. References 1 : Flushing: long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology1989; 33: 175. Google Scholar 2 : Male climacteric after orchiectomy in patient with prostatic cancer. Urology1980; 16: 620. Google Scholar 3 : Climacteric flushing in a man. Brit. Med. J.1983; 287: 262. Google Scholar 4 : A qualitative approach to defining “hot flashes” in men. Urol. Nurs.1994; 14: 155. Google Scholar 5 : Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J. Urol.1994; 151: 634. Abstract, Google Scholar 6 : Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology1992; 39: 108. Google Scholar 7 : Megestrol acetate for the prevention of hot flashes. New Engl. J. Med.1994; 331: 347. Google Scholar 8 : Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate of cancer: expansion of the antiandrogen withdrawal syndrome. J. Urol.1995; 153: 1946. Link, Google Scholar 9 : Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin. Proc.1997; 72: 932. Google Scholar 10 : Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer1998; 82: 1784. Google Scholar 11 : Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann. Clin. Psychiatr.1997; 9: 157. Google Scholar 12 : Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J. Clin. Oncol.1998; 16: 2377. Google Scholar 13 : . New York: John Wiley and Sons1971: 127. Google Scholar 14 : Emergency of adverse events following discontinuation of treatment with extended-release venlafaxine. Amer. J. Psychiatr.1997; 154: 1760. Google Scholar 15 : Cyproterone acetate in treatment of post-orchiectomy hot flushes. Double-blind cross-over trial. Lancet1983; 2: 1336. Google Scholar From the Divisions of Medical Oncology and Radiation Oncology, and Departments of Biostatistics and Urology, Mayo Clinic, Rochester, Minnesota, and Department of Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida(Loprinzi) Requests for reprints: Division of Medical Oncology, Mayo Clinic, 200 First St. S. W., Rochester, Minnesota 55905.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 162Issue 1July 1999Page: 98-102 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information SUSAN K. QUELLA More articles by this author CHARLES L. LOPRINZI More articles by this author JEFF SLOAN More articles by this author PAUL NOVOTNY More articles by this author EDITH A. PEREZ More articles by this author PATRICK A. BURCH More articles by this author STANLEY J. ANTOLAK More articles by this author THOMAS M. PISANSKY More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2104660811 created "2016-06-24" @default.
• W2104660811 creator A5001125083 @default.
• W2104660811 creator A5008767553 @default.
• W2104660811 creator A5013202100 @default.
• W2104660811 creator A5019525982 @default.
• W2104660811 creator A5050514405 @default.
• W2104660811 creator A5065306642 @default.
• W2104660811 creator A5070931161 @default.
• W2104660811 creator A5072257104 @default.
• W2104660811 date "1999-07-01" @default.
• W2104660811 modified "2023-10-06" @default.
• W2104660811 title "PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER" @default.
• W2104660811 cites W149320854 @default.
• W2104660811 cites W1865738444 @default.
• W2104660811 cites W1984889864 @default.
• W2104660811 cites W1986043820 @default.
• W2104660811 cites W1990752843 @default.
• W2104660811 cites W2055825014 @default.
• W2104660811 cites W2073407645 @default.
• W2104660811 cites W2095559783 @default.
• W2104660811 cites W2131968197 @default.
• W2104660811 cites W2321102288 @default.
• W2104660811 cites W4231296637 @default.
• W2104660811 cites W4241892512 @default.
• W2104660811 cites W4255053419 @default.
• W2104660811 doi "https://doi.org/10.1097/00005392-199907000-00024" @default.
• W2104660811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10379749" @default.
• W2104660811 hasPublicationYear "1999" @default.
• W2104660811 type Work @default.
• W2104660811 sameAs 2104660811 @default.
• W2104660811 citedByCount "129" @default.
• W2104660811 countsByYear W21046608112012 @default.
• W2104660811 countsByYear W21046608112013 @default.
• W2104660811 countsByYear W21046608112014 @default.
• W2104660811 countsByYear W21046608112015 @default.
• W2104660811 countsByYear W21046608112016 @default.
• W2104660811 countsByYear W21046608112017 @default.
• W2104660811 countsByYear W21046608112018 @default.
• W2104660811 countsByYear W21046608112021 @default.
• W2104660811 countsByYear W21046608112022 @default.
• W2104660811 countsByYear W21046608112023 @default.
• W2104660811 crossrefType "journal-article" @default.
• W2104660811 hasAuthorship W2104660811A5001125083 @default.
• W2104660811 hasAuthorship W2104660811A5008767553 @default.
• W2104660811 hasAuthorship W2104660811A5013202100 @default.
• W2104660811 hasAuthorship W2104660811A5019525982 @default.
• W2104660811 hasAuthorship W2104660811A5050514405 @default.
• W2104660811 hasAuthorship W2104660811A5065306642 @default.
• W2104660811 hasAuthorship W2104660811A5070931161 @default.
• W2104660811 hasAuthorship W2104660811A5072257104 @default.
• W2104660811 hasConcept C121608353 @default.
• W2104660811 hasConcept C126322002 @default.
• W2104660811 hasConcept C126894567 @default.
• W2104660811 hasConcept C2776466888 @default.
• W2104660811 hasConcept C2777899217 @default.
• W2104660811 hasConcept C2777911890 @default.
• W2104660811 hasConcept C2778902805 @default.
• W2104660811 hasConcept C2779177272 @default.
• W2104660811 hasConcept C2780192828 @default.
• W2104660811 hasConcept C2781161787 @default.
• W2104660811 hasConcept C2910630342 @default.
• W2104660811 hasConcept C71315377 @default.
• W2104660811 hasConcept C71924100 @default.
• W2104660811 hasConceptScore W2104660811C121608353 @default.
• W2104660811 hasConceptScore W2104660811C126322002 @default.
• W2104660811 hasConceptScore W2104660811C126894567 @default.
• W2104660811 hasConceptScore W2104660811C2776466888 @default.
• W2104660811 hasConceptScore W2104660811C2777899217 @default.
• W2104660811 hasConceptScore W2104660811C2777911890 @default.
• W2104660811 hasConceptScore W2104660811C2778902805 @default.
• W2104660811 hasConceptScore W2104660811C2779177272 @default.
• W2104660811 hasConceptScore W2104660811C2780192828 @default.
• W2104660811 hasConceptScore W2104660811C2781161787 @default.
• W2104660811 hasConceptScore W2104660811C2910630342 @default.
• W2104660811 hasConceptScore W2104660811C71315377 @default.
• W2104660811 hasConceptScore W2104660811C71924100 @default.
• W2104660811 hasIssue "1" @default.
• W2104660811 hasLocation W21046608111 @default.
• W2104660811 hasLocation W21046608112 @default.
• W2104660811 hasOpenAccess W2104660811 @default.
• W2104660811 hasPrimaryLocation W21046608111 @default.
• W2104660811 hasRelatedWork W2005958584 @default.
• W2104660811 hasRelatedWork W2071161597 @default.
• W2104660811 hasRelatedWork W2078067450 @default.
• W2104660811 hasRelatedWork W2080612280 @default.
• W2104660811 hasRelatedWork W2140675573 @default.
• W2104660811 hasRelatedWork W2478516995 @default.
• W2104660811 hasRelatedWork W2811482540 @default.
• W2104660811 hasRelatedWork W4233043649 @default.
• W2104660811 hasRelatedWork W4319748405 @default.
• W2104660811 hasRelatedWork W2554788055 @default.
• W2104660811 hasVolume "162" @default.
• W2104660811 isParatext "false" @default.
• W2104660811 isRetracted "false" @default.
• W2104660811 magId "2104660811" @default.
• W2104660811 workType "article" @default.